Paroxysmal Nocturnal Hemoglobinuria Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
발작성 야간 혈색소뇨증(PNH) 시장- 조사 범위
TMR의 조사 보고서 "발작성 야간 혈색소뇨증(PNH) 세계 시장"은 2024년부터 2034년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사했습니다. 이 보고서는 2024년을 기준연도로, 2034년을 예측 연도로 하여 2018년부터 2034년까지 발작성 야간 혈색소뇨증(PNH) 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 발작성 야간 혈색소뇨증(PNH) 시장의 연평균 복합 성장률(CAGR%)도 제시합니다.
이 보고서는 광범위한 1차 연구, KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체와의 인터뷰, 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 문서 등을 참조하여 발작성 야간 혈색소뇨증(PNH) 시장을 추론했습니다, 발작성 야간 혈색소뇨증(PNH) 시장을 추론했습니다.
| 시장 현황 |
| 2023년 시장 규모 |
38억 달러 |
| 2034년 시장 규모 |
117억 달러 |
| CAGR |
10.8% |
이 보고서는 세계 발작성 야간 혈색소뇨증(PNH) 시장의 경쟁 환경을 조사했습니다. 세계 발작성 야간 혈색소뇨증(PNH) 시장에서 활동하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성으로 프로파일링되었습니다. 기업 개요, 재무 상태, 최근 동향, SWOT 등은 세계 발작성 야간 혈색소뇨증(PNH) 시장에서 활동하는 주요 업체들의 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
- 서론
- 개요
- 시장 역학
- 세계 시장 분석과 예측, 2020-2034년
제5장 주요 인사이트
- 파이프라인 분석
- 주요 제품/브랜드 분석
- 주요 M&A
- COVID-19의 산업에 대한 영향
제6장 세계 시장 분석과 예측 : 치료별
- 서론과 정의
- 주요 조사 결과와 발전
- 시장 매출 예측 : 치료별, 2020-2034년
- 시장의 매력 분석 : 치료별
제7장 세계 시장 분석과 예측 : 최종사용자별
- 서론과 정의
- 주요 조사 결과와 발전
- 시장 매출 예측 : 최종사용자별, 2020-2034년
- 병원 및 클리닉
- 재택 치료
- 기타(연구기관 등)
- 시장의 매력 분석 : 최종사용자별
제8장 세계 시장 분석과 예측 : 지역별
- 주요 조사 결과
- 시장 매출 예측 : 지역별, 2020-2034년
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- 시장의 매력 분석 : 지역별
제9장 북미 시장 분석과 예측
제10장 유럽 시장 분석과 예측
제11장 아시아태평양 시장 분석과 예측
제12장 라틴아메리카 시장 분석과 예측
제13장 중동 및 아프리카 시장 분석과 예측
제14장 경쟁 구도
- 시장 기업 - 경쟁 매트릭스(기업 Tier 및 규모별)
- 시장 점유율 분석 : 기업별(2023년)
- 기업 개요
- Alexion Pharmaceuticals, Inc.
- Apellis Pharmaceuticals
- Genentec, Inc.
- Novartis AG
- The Takeda Pharmaceutical Company Limited
- Kira Pharmaceuticals
- F. Hoffman-La Roche AG
- Akari Therapeutics PLC
- Omeros Corporation
- Regeneron Pharmaceuticals, Inc.
LSH
Paroxysmal Nocturnal Hemoglobinuria Market - Scope of Report
TMR's report on the global paroxysmal nocturnal hemoglobinuria market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global paroxysmal nocturnal hemoglobinuria market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global paroxysmal nocturnal hemoglobinuria market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the paroxysmal nocturnal hemoglobinuria market.
| Market Snapshot |
|---|
| Market Value in 2023 | US$ 3.8 Bn |
| Market Value in 2034 | US$ 11.7 Bn |
| CAGR | 10.8% |
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global paroxysmal nocturnal hemoglobinuria market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global paroxysmal nocturnal hemoglobinuria market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global paroxysmal nocturnal hemoglobinuria market.
The report delves into the competitive landscape of the global paroxysmal nocturnal hemoglobinuria market. Key players operating in the global paroxysmal nocturnal hemoglobinuria market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global paroxysmal nocturnal hemoglobinuria market profiled in this report.
Key Questions Answered in Global paroxysmal nocturnal hemoglobinuria Market Report:
- What is the sales/revenue generated by paroxysmal nocturnal hemoglobinuria across all regions during the forecast period?
- What are the opportunities in the global paroxysmal nocturnal hemoglobinuria market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2034?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
Paroxysmal Nocturnal Hemoglobinuria Market - Research Objectives and Research Approach
The comprehensive report on the global paroxysmal nocturnal hemoglobinuria market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global paroxysmal nocturnal hemoglobinuria market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global paroxysmal nocturnal hemoglobinuria market.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Paroxysmal Nocturnal Hemoglobinuria Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Product Definition
- 4.1.2. Industry Evolution/Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, 2020-2034
5. Key Insights
- 5.1. Pipeline Analysis
- 5.2. Key Product/Brand Analysis
- 5.3. Key Mergers & Acquisitions
- 5.4. COVID-19 Pandemic Impact on Industry
6. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, by Treatment
- 6.1. Introduction & Definition
- 6.2. Key Findings/Developments
- 6.3. Market Value Forecast, by Treatment, 2020-2034
- 6.3.1. Medication
- 6.3.1.1. Eculizumab
- 6.3.1.2. Ravulizumab
- 6.3.2. Supplements
- 6.3.3. Blood Transfusion
- 6.3.4. Bone Marrow Transplant
- 6.3.5. Immunosuppressive Therapy
- 6.4. Market Attractiveness Analysis, by Treatment
7. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, by End-user
- 7.1. Introduction & Definition
- 7.2. Key Findings/Developments
- 7.3. Market Value Forecast, by End-user, 2020-2034
- 7.3.1. Hospitals & Clinics
- 7.3.2. Homecare Settings
- 7.3.3. Others (Research Institutes, etc.)
- 7.4. Market Attractiveness Analysis, by End-user
8. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, by Region
- 8.1. Key Findings
- 8.2. Market Value Forecast, by Region, 2020-2034
- 8.2.1. North America
- 8.2.2. Europe
- 8.2.3. Asia Pacific
- 8.2.4. Latin America
- 8.2.5. Middle East & Africa
- 8.3. Market Attractiveness Analysis, by Region
9. North America Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast
- 9.1. Introduction
- 9.2. Key Findings
- 9.3. Market Value Forecast, by Treatment, 2020-2034
- 9.3.1. Medication
- 9.3.1.1. Eculizumab
- 9.3.1.2. Ravulizumab
- 9.3.2. Supplements
- 9.3.3. Blood Transfusion
- 9.3.4. Bone Marrow Transplant
- 9.3.5. Immunosuppressive Therapy
- 9.4. Market Value Forecast, by End-user, 2020-2034
- 9.4.1. Hospitals & Clinics
- 9.4.2. Homecare Settings
- 9.4.3. Others (Research Institutes, etc.)
- 9.5. Market Value Forecast, by Country, 2020-2034
- 9.5.1. U.S.
- 9.5.2. Canada
- 9.6. Market Attractiveness Analysis
- 9.6.1. By Treatment
- 9.6.2. By End-user
- 9.6.3. By Country
10. Europe Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast
- 10.1. Introduction
- 10.2. Key Findings
- 10.3. Market Value Forecast, by Treatment, 2020-2034
- 10.3.1. Medication
- 10.3.1.1. Eculizumab
- 10.3.1.2. Ravulizumab
- 10.3.2. Supplements
- 10.3.3. Blood Transfusion
- 10.3.4. Bone Marrow Transplant
- 10.3.5. Immunosuppressive Therapy
- 10.4. Market Value Forecast, by End-user, 2020-2034
- 10.4.1. Hospitals & Clinics
- 10.4.2. Homecare Settings
- 10.4.3. Others (Research Institutes, etc.)
- 10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
- 10.5.1. Germany
- 10.5.2. U.K.
- 10.5.3. France
- 10.5.4. Italy
- 10.5.5. Spain
- 10.5.6. Rest of Europe
- 10.6. Market Attractiveness Analysis
- 10.6.1. By Treatment
- 10.6.2. By End-user
- 10.6.3. By Country/Sub-region
11. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast
- 11.1. Introduction
- 11.2. Key Findings
- 11.3. Market Value Forecast, by Treatment, 2020-2034
- 11.3.1. Medication
- 11.3.1.1. Eculizumab
- 11.3.1.2. Ravulizumab
- 11.3.2. Supplements
- 11.3.3. Blood Transfusion
- 11.3.4. Bone Marrow Transplant
- 11.3.5. Immunosuppressive Therapy
- 11.4. Market Value Forecast, by End-user, 2020-2034
- 11.4.1. Hospitals & Clinics
- 11.4.2. Homecare Settings
- 11.4.3. Others (Research Institutes, etc.)
- 11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
- 11.5.1. China
- 11.5.2. Japan
- 11.5.3. India
- 11.5.4. Australia & New Zealand
- 11.5.5. Rest of Asia Pacific
- 11.6. Market Attractiveness Analysis
- 11.6.1. By Treatment
- 11.6.2. By End-user
- 11.6.3. By Country/Sub-region
12. Latin America Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Key Findings
- 12.3. Market Value Forecast, by Treatment, 2020-2034
- 12.3.1. Medication
- 12.3.1.1. Eculizumab
- 12.3.1.2. Ravulizumab
- 12.3.2. Supplements
- 12.3.3. Blood Transfusion
- 12.3.4. Bone Marrow Transplant
- 12.3.5. Immunosuppressive Therapy
- 12.4. Market Value Forecast, by End-user, 2020-2034
- 12.4.1. Hospitals & Clinics
- 12.4.2. Homecare Settings
- 12.4.3. Others (Research Institutes, etc.)
- 12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
- 12.5.1. Brazil
- 12.5.2. Mexico
- 12.5.3. Rest of Latin America
- 12.6. Market Attractiveness Analysis
- 12.6.1. By Treatment
- 12.6.2. By End-user
- 12.6.3. By Country/Sub-region
13. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Key Findings
- 13.3. Market Value Forecast, by Treatment, 2020-2034
- 13.3.1. Medication
- 13.3.1.1. Eculizumab
- 13.3.1.2. Ravulizumab
- 13.3.2. Supplements
- 13.3.3. Blood Transfusion
- 13.3.4. Bone Marrow Transplant
- 13.3.5. Immunosuppressive Therapy
- 13.4. Market Value Forecast, by End-user, 2020-2034
- 13.4.1. Hospitals & Clinics
- 13.4.2. Homecare Settings
- 13.4.3. Others (Research Institutes, etc.)
- 13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
- 13.5.1. GCC Countries
- 13.5.2. South Africa
- 13.5.3. Rest of Middle East & Africa
- 13.6. Market Attractiveness Analysis
- 13.6.1. By Treatment
- 13.6.2. By End-user
- 13.6.3. By Country/Sub-region
14. Competition Landscape
- 14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
- 14.2. Market Share Analysis, by Company (2023)
- 14.3. Company Profiles
- 14.3.1. Alexion Pharmaceuticals, Inc.
- 14.3.1.1. Company Overview
- 14.3.1.2. Product Portfolio
- 14.3.1.3. SWOT Analysis
- 14.3.1.4. Financial Overview
- 14.3.1.5. Strategic Overview
- 14.3.2. Apellis Pharmaceuticals
- 14.3.2.1. Company Overview
- 14.3.2.2. Product Portfolio
- 14.3.2.3. SWOT Analysis
- 14.3.2.4. Financial Overview
- 14.3.2.5. Strategic Overview
- 14.3.3. Genentec, Inc.
- 14.3.3.1. Company Overview
- 14.3.3.2. Product Portfolio
- 14.3.3.3. SWOT Analysis
- 14.3.3.4. Financial Overview
- 14.3.3.5. Strategic Overview
- 14.3.4. Novartis AG
- 14.3.4.1. Company Overview
- 14.3.4.2. Product Portfolio
- 14.3.4.3. SWOT Analysis
- 14.3.4.4. Financial Overview
- 14.3.4.5. Strategic Overview
- 14.3.5. The Takeda Pharmaceutical Company Limited
- 14.3.5.1. Company Overview
- 14.3.5.2. Product Portfolio
- 14.3.5.3. SWOT Analysis
- 14.3.5.4. Financial Overview
- 14.3.5.5. Strategic Overview
- 14.3.6. Kira Pharmaceuticals
- 14.3.6.1. Company Overview
- 14.3.6.2. Product Portfolio
- 14.3.6.3. SWOT Analysis
- 14.3.6.4. Financial Overview
- 14.3.6.5. Strategic Overview
- 14.3.7. F. Hoffman-La Roche AG
- 14.3.7.1. Company Overview
- 14.3.7.2. Product Portfolio
- 14.3.7.3. SWOT Analysis
- 14.3.7.4. Financial Overview
- 14.3.7.5. Strategic Overview
- 14.3.8. Akari Therapeutics PLC
- 14.3.8.1. Company Overview
- 14.3.8.2. Product Portfolio
- 14.3.8.3. SWOT Analysis
- 14.3.8.4. Financial Overview
- 14.3.8.5. Strategic Overview
- 14.3.9. Omeros Corporation
- 14.3.9.1. Company Overview
- 14.3.9.2. Product Portfolio
- 14.3.9.3. SWOT Analysis
- 14.3.9.4. Financial Overview
- 14.3.9.5. Strategic Overview
- 14.3.10. Regeneron Pharmaceuticals, Inc.
- 14.3.10.1. Company Overview
- 14.3.10.2. Product Portfolio
- 14.3.10.3. SWOT Analysis
- 14.3.10.4. Financial Overview
- 14.3.10.5. Strategic Overview
